Companies · Biotechnology

Alpha Cognition Inc.

VANCOUVER · Biotechnology

Diligence memoA one-page analyst read on Alpha Cognition Inc. — recommendation, valuation, rhythm, risks.
$27.6M
Total raised · real
16
Rounds
0.1×
Latest step-up
Top 28%
Sector rank · raised
Series A
Latest stage · inferred · Mon Oct 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Alpha Cognition Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Quiet
  • Last raise 20 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Alpha Cognition Inc. is one of 4293 Biotechnology companies tracked from VANCOUVER. By capital raised it ranks in the upper tier (ahead of 73% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-10-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2016-04-04 Raised $385K (real) Modeled valuation $21M (est)Pre-Seed2016Pre-Seed · 2017-02-28 Raised $200K (real) Modeled valuation $11M (est)Pre-Seed2017Seed · 2018-07-05 Raised $2.0M (real) Modeled valuation $89M (est)Seed2018Series A · 2019-08-30 Raised $6.0M (real) Modeled valuation $215M (est)Series A2019Series A · 2020-04-27 Raised $1.9M (real) Modeled valuation $69M (est)Series A2020Series A · 2020-12-18 Raised $1.5M (real) Modeled valuation $42M (est)Series A2020Series A · 2021-10-01 Raised $425K (real) Modeled valuation $8.4M (est)Series A2021Series A · 2023-02-16 Raised $1.8M (real) Modeled valuation $19M (est)Series A2023Series A · 2023-03-15 Raised $1.3M (real) Modeled valuation $13M (est)Series A2023Series A · 2023-08-31 Raised $1.3M (real) Modeled valuation $9.9M (est)Series A2023Series A · 2023-10-16 Raised $344K (real) Modeled valuation $2.5M (est)Series A2023Series A · 2023-11-08 Raised $1.0M (real) Modeled valuation $7.2M (est)Series A2023Series A · 2023-12-22 Raised $1.8M (real) Modeled valuation $12M (est)Series A2023Series A · 2024-01-24 Raised $2.8M (real) Modeled valuation $18M (est)Series A2024Series A · 2024-09-24 Raised $4.5M (real) Modeled valuation $21M (est)Series A2024Series A · 2024-10-21 Raised $347K (real) Modeled valuation $1.6M (est)Series A2024Cumulative $28M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$385K · 2016
Pre-Seed extension$200K · 2017
Seed$2.0M · 2018
Series A$6.0M · 2019
Series A extension$1.9M · 2020
Series A extension$1.5M · 2020
Series A extension$425K · 2021
Series A extension$1.8M · 2023
Series A extension$1.3M · 2023
Series A extension$1.3M · 2023
Series A extension$344K · 2023
Series A extension$1.0M · 2023
Series A extension$1.8M · 2023
Series A extension$2.8M · 2024
Series A extension$4.5M · 2024
Series A extension$347K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.6M
Base estimate est.
$378K
Conservative case
$3.2M
Upside case
$1.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $21.3M · 2016-04-042016Pre-Seed · modeled $11.0M · 2017-02-28Seed · modeled $88.8M · 2018-07-05Series A · modeled $215.1M · 2019-08-30Series A · modeled $69.2M · 2020-04-27Series A · modeled $42.1M · 2020-12-18Series A · modeled $8.4M · 2021-10-01Series A · modeled $18.8M · 2023-02-16Series A · modeled $12.6M · 2023-03-15Series A · modeled $9.9M · 2023-08-31Series A · modeled $2.5M · 2023-10-16Series A · modeled $7.2M · 2023-11-08Series A · modeled $11.9M · 2023-12-22Series A · modeled $18.4M · 2024-01-24Series A · modeled $21.3M · 2024-09-24Series A · modeled $1.6M · 2024-10-212024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
1.7 yr
Elapsed time used
1.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$3.2M/yr
Capital velocity
10.2 yr
On record since
2016
First round
16
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.8× above median
This company$27.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$347K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.6M
Sector median$64.2M

Raised more than 73% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #299 of 303.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Alpha Cognition Inc. (this company) Raised $27.6M · modeled $1.6M (est)Alpha Cognition Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Alpha Cognition Inc. this companySeries A$27.6M$1.6M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$385K2016-04-04$2.1M$21.3M85%
Pre-Seed$200K2017-02-28$1.1M$11.0M90%
Seed$2.0M2018-07-05$10.0M$88.8M90%
Series A$6.0M2019-08-30$27.1M$215.1M90%
Series A$1.9M2020-04-27$8.7M$69.2M90%
Series A$1.5M2020-12-18$6.6M$42.1M90%
Series A$425K2021-10-01$1.9M$8.4M90%
Series A$1.8M2023-02-16$8.4M$18.8M90%
Series A$1.3M2023-03-15$5.8M$12.6M90%
Series A$1.3M2023-08-31$5.7M$9.9M90%
Series A$344K2023-10-16$1.6M$2.5M90%
Series A$1.0M2023-11-08$4.6M$7.2M90%
Series A$1.8M2023-12-22$8.0M$11.9M90%
Series A$2.8M2024-01-24$12.9M$18.4M90%
Series A$4.5M2024-09-24$20.7M$21.3M90%
Series A$347K2024-10-21$1.6M$1.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$385K2016-04-04
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$200K2017-02-28
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  3. Seed$2.0M2018-07-05
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 10.0× larger than the prior — scaling up.
    • 6 investors on this round.
  4. Series A$6.0M2019-08-30
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 3.0× larger than the prior — scaling up.
    • 14 investors on this round.
  5. Series A$1.9M2020-04-27
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 3.1× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  6. Series A$1.5M2020-12-18
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 18 investors on this round.
  7. Series A$425K2021-10-01
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 3.4× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  8. Series A$1.8M2023-02-16
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 4.3× larger than the prior — scaling up.
    • 8 investors on this round.
  9. Series A$1.3M2023-03-15
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 14 investors on this round.
  10. Series A$1.3M2023-08-31
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 28 investors on this round.
  11. Series A$344K2023-10-16
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 3.7× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  12. Series A$1.0M2023-11-08
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.9× larger than the prior — scaling up.
    • 13 investors on this round.
  13. Series A$1.8M2023-12-22
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 30 investors on this round.
  14. Series A$2.8M2024-01-24
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 60 investors on this round.
  15. Series A$4.5M2024-09-24
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 22 investors on this round.
  16. Series A$347K2024-10-21
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 13.1× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~7mo cadence
$347K
Modeled next size est.range $347K$555K
0.1×
Last step-up
$3.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Frederick Sancilio3 other2021-10
Kenneth A. Cawkell2 other2016-04
Kenneth Cawkell2 other2021-10
Michael McFadden2 other2021-10
Denis A. Kay1 other2020-04
Jeremy Wright1 other2021-10
John Havens1 other2021-10
Alfred A. Maelicke2016-04
Anthony A. Giovinazzo2017-02
Denis Kay2021-10
Denis P. Kay2019-08
Don Kalkofen2023-02
Erich A. Mohr2016-04
Frederick A. Sancilio2020-04
Henry Du2024-10
Jay Rob Yoo2024-09
Jeremy Mertz2021-10
John A. Havens2020-04
John P. Havens2019-08
John Rob Havens2024-09
Lauren D'Angelo2021-10
Lauren Rob D'Angelo2024-09
Len A. Mertz2016-04
Len Mertz2021-10
Registry & provenance

Alpha Cognition Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1655923
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Neurodyn Life Sciences Inc.BiotechnologySeed$5.2M$28.9Mnetwork2 shared operators · same sector
Cynaptec Pharmaceuticals, Inc.BiotechnologySeries A$6.0M$21.7Mnetwork1 shared operator · same sector · same stage
Tangen Biosciences, Inc.BiotechnologySeries A$28.4M$4.2Msame sector · same stage
Thunder Biotech, Inc.BiotechnologySeries A$24.5M$634Ksame sector · same stage
Halia Therapeutics, Inc.BiotechnologySeries A$23.9M$1.1Msame sector · same stage
Scorpius Holdings, Inc.BiotechnologySeries A$23.6M$3.9Msame sector · same stage
Artelo Biosciences, Inc.BiotechnologySeries A$23.2M$723Ksame sector · same stage
Trethera CorpBiotechnologySeries A$35.1M$881Ksame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cognigenics, Inc.BiotechnologySeed$24.0M86%
Intuitive Biosciences, Inc.BiotechnologySeed$54.3M85%
Brain Code IncBiotechnologySeries A$33.0M85%
Brainbox Solutions, Inc.BiotechnologySeries B$67.8M85%
Minerva Neurosciences, Inc.BiotechnologySeries B$219.6M85%
Alto Neuroscience, Inc.BiotechnologySeries C$271.1M85%
Trait Biosciences Inc.BiotechnologySeries A$28.5M84%
NeuroQuest Development Center, Inc.BiotechnologyPre-Seed$3.0M84%
Frequently asked
How much funding has Alpha Cognition Inc. raised?
Alpha Cognition Inc. has raised approximately $27.6M in disclosed capital across 16 recorded financing rounds, aggregated from public filings.
What is Alpha Cognition Inc.'s estimated valuation?
Provath's modeled valuation for Alpha Cognition Inc. is approximately $1.6M (modeled range $378K–$3.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Alpha Cognition Inc. at?
Alpha Cognition Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Oct 21.
What does Alpha Cognition Inc. do and where is it based?
Alpha Cognition Inc. operates in the Biotechnology sector, based in VANCOUVER.
Explore related

See where Alpha Cognition Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Alpha Cognition Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.